

## Velphoro (sucroferric oxyhydroxide)

### Disclaimer

*Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.*

*Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.*

Velphoro (sucroferric oxyhydroxide)	1
Summary	2
Definitions	2
Clinical Indications	3
Medical Necessity Criteria for Clinical Review	3
General Medical Necessity Criteria	3
Medical Necessity Criteria for Initial Clinical Review	4
Initial Indication-Specific Criteria	4
Hyperphosphatemia in Chronic Kidney Disease on Dialysis	4
Medical Necessity Criteria for Subsequent Clinical Review	5
Subsequent Indication-Specific Criteria	5
Hyperphosphatemia in Chronic Kidney Disease on Dialysis	5
Experimental / Investigational, or unproven	5
References	6
Clinical Guideline Revision / History Information	7

## Summary

Chronic kidney disease (CKD) is a progressive condition characterized by gradual loss of kidney function over time. As CKD advances, the kidneys have difficulty eliminating waste products from the bloodstream. One of these waste products is phosphorus, an essential mineral needed for bone health, energy production, and other cellular functions.

In advanced CKD and end-stage renal disease (ESRD), impaired kidney function leads to hyperphosphatemia, or abnormally elevated blood phosphorus levels. If left uncontrolled, hyperphosphatemia can cause serious complications like abnormal bone mineralization, vascular calcification, and increased risk of cardiovascular mortality.

Hyperphosphatemia is typically managed first with lifestyle modification if the phosphate levels are no greater than (>) 5.5 mg/dl. This may include reducing phosphate in the diet (e.g., processed foods, sodas, meat and eggs). Other management strategies include optimizing dialysis if they are receiving dialysis to improve phosphate removal, and utilizing phosphate binders. Phosphate binders bind to dietary phosphate in the gastrointestinal tract and limit intestinal absorption and ultimately reducing serum phosphate levels; they are further divided into non-calcium-containing and calcium-containing binders. Non-calcium-containing binders include lanthanum carbonate (Fosrenol), sevelamer (Renvela), ferric citrate (Auryxia), and sucroferric oxyhydroxide (Velphoro). Calcium-containing phosphate binders include calcium carbonate (e.g., Tums), and calcium acetate (PhosLo, Calphron, Phoslyra).

Velphoro (sucroferric oxyhydroxide) is approved for the control of serum phosphorus in those 9 years of age and older with CKD on dialysis. While Velphoro (sucroferric oxyhydroxide) can help control elevated blood phosphorus levels, it does not cure CKD or restore normal kidney function. It is one component of a comprehensive treatment plan for advanced CKD and ESRD which may also include:

1. Dietary phosphorus restriction.
2. Dialysis to remove excess phosphorus.
3. Other phosphate binder medications.

## Definitions

“Chronic Kidney Disease (CKD)” is a progressive condition characterized by gradual loss of kidney function over time.

“Dialysis” is a treatment that filters wastes, salts, and fluid from the blood when the kidneys are no longer healthy enough to do this on their own. Two main types are hemodialysis and peritoneal dialysis.

“Documentation” refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or
- Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

“End-Stage Renal Disease (ESRD)” is the final stage of chronic kidney disease when the kidneys can no longer function at the level needed to sustain life. Patients typically require renal replacement therapy such as dialysis or kidney transplantation.

“Hemodialysis” is a type of dialysis where a machine filters wastes, salts, and fluid from the blood when the kidneys are no longer healthy enough.

“Hyperphosphatemia” is abnormally elevated level of phosphate in the blood, defined as a serum phosphate concentration greater than 4.5 mg/dL in patients with ESRD. For adults on dialysis, serum phosphorus >5.5 mg/dL (1.78 mmol/L) is an indication for treatment. Pediatric hyperphosphatemia is defined as serum phosphorus above the age-appropriate upper limit of normal for the reporting laboratory. For pediatric on dialysis, this generally corresponds to >6.0 mg/dL in children 1-12 years of age and >5.5 mg/dL during adolescence.

“No evidence of” indicates that the reviewer has not identified any records of the specified item or condition within the submitted materials or claims history. In the absence of such evidence, the member is considered eligible. If any evidence of the item or condition is present upon review of the request, the member does not qualify.

“Peritoneal Dialysis” is a type of dialysis where fluid is put into the abdomen to absorb wastes and fluid from small blood vessels.

“Phosphate Binders” are medications that bind dietary phosphate in the gastrointestinal tract to reduce absorption and lower serum phosphate levels. Examples include calcium acetate, sevelamer carbonate, sevelamer hydrochloride, and lanthanum carbonate.

“Serum Phosphate” is a measurement of the amount of phosphate in the blood, reported in mg/dL or mmol/L. Normal range is 2.5-4.5 mg/dL in adults. Levels higher than 4.5 mg/dL indicate hyperphosphatemia.

“[s]” indicates state mandates may apply.

## Clinical Indications

### Medical Necessity Criteria for Clinical Review

#### General Medical Necessity Criteria

The Plan considers Velporo (sucroferric oxyhydroxide) medically necessary when ALL of the following criteria are met:

1. Velporo (sucroferric oxyhydroxide) is prescribed by or in consultation with a nephrologist; *AND*

2. The member is 9 years of age or older; *AND*
3. Velphoro (sucroferric oxyhydroxide) is prescribed at a dose that does not exceed 3,000 mg per day (6 tablets per day); *AND*
4. The member meets the applicable [Medical Necessity Criteria for Initial Clinical Review](#) or [Subsequent Clinical Review](#) listed below.

#### Medical Necessity Criteria for Initial Clinical Review

##### Initial Indication-Specific Criteria

##### Hyperphosphatemia in Chronic Kidney Disease on Dialysis

The Plan considers Velphoro (sucroferric oxyhydroxide) medically necessary when ALL of the following criteria are met:

- 5.
6. The member meets the above [General Medical Necessity Criteria](#); *AND*
7. The member has a diagnosis of chronic kidney disease (CKD); *AND*
8. The member is on dialysis; *AND*
9. The member has documented evidence of:
  - a. Hyperphosphatemia, characterized by a serum phosphate level greater than (>) 5.5 mg/dL in adults OR above the age-appropriate upper limit of normal per the reporting laboratory in pediatric members; *and*
  - b. Inadequate control of serum phosphate despite adherence to dietary restrictions and optimized dialysis regimen (if appropriate); *AND*
10. The member is currently undergoing hemodialysis or peritoneal dialysis; *AND*
11. The member meets ONE of the following<sup>[5]</sup>:
  - a. For adults 18 years of age and older, the member is unable to use, or has tried and failed ONE (1) of the following:
    - i. calcium acetate (PhosLo); *or*
    - ii. lanthanum carbonate chewable tablet (Fosrenol); *or*
    - iii. sevelamer (Renvela); *or*
  - b. For pediatrics 9 to 17 years of age with a body surface area of at least 0.75m<sup>2</sup>, the member is unable to use, or has tried and failed sevelamer carbonate (Renvela).

If the above prior authorization criteria are met, Velphoro (sucroferric oxyhydroxide) will be approved for up to 12 months.<sup>[5]</sup>

*Continued Care*

## Medical Necessity Criteria for Subsequent Clinical Review

### Subsequent Indication-Specific Criteria

#### Hyperphosphatemia in Chronic Kidney Disease on Dialysis

The Plan considers Velphoro (sucroferric oxyhydroxide) medically necessary when ALL of the following criteria are met:

1. The member meets the above applicable [General Medical Necessity Criteria](#) and/or [Initial Clinical Review](#); *AND*
2. The member has experienced clinical benefit from Velphoro (sucroferric oxyhydroxide) treatment as validated by clinical documentation showing ONE of the following within the last 3 months:
  - a. Serum phosphate level reduced to target range (3.5-5.5 mg/dL for adults or age-appropriate range per the reporting laboratory for pediatrics); *or*
  - b. A reduction in serum phosphorus concentration from baseline.

If the above reauthorization criteria are met, the requested product will be authorized for up to 12 months.<sup>[s]</sup>

#### [Experimental / Investigational, or unproven](#)<sup>[s]</sup>

Velphoro (sucroferric oxyhydroxide) for any other indication or use is considered experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Anemia. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of anemia.
- Anemia of Chronic Disease. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of anemia of chronic disease.
- Chronic Heart Failure (CHF). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of CHF.
- Chronic Lymphocytic Leukemia (CLL). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of CLL.
- Colorectal Neoplasms. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of colorectal neoplasms.
- Crohn's Disease (CD). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of CD.
- Hip Arthropathy. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of hip arthropathy.
- Hip Fracture. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of hip fracture.
- Hypoalbuminemia. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of hypoalbuminemia.

- Inflammatory Bowel Diseases (IBD). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of IBD.
- Iron Deficiency (ID). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of ID.
- Iron Deficiency Anemia (IDA) in Childbirth. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of IDA in childbirth.
- Iron Deficiency Anemia (IDA). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of IDA.
- Knee Arthropathy. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of knee arthropathy.
- Multiple Myeloma (MM). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of MM.
- Non-Hodgkin's Lymphoma (NHL). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of NHL.
- Osteoarthritis (OA). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of OA.
- Perioperative Blood Conservation. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of perioperative blood conservation.
- Restless Legs Syndrome (RLS). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of RLS.
- Ulcerative Colitis. There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of UC.
- Unexplained Anemia (UAE). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of UEA.
- Variola Major (Smallpox). There are no high quality studies to support the safety and efficacy of Velphoro (sucroferric oxyhydroxide) for the management of smallpox.

## References

1. Chen TK et al. Chronic kidney disease diagnosis and management: a review. *JAMA*. 2019;322(13):1294-1304.
2. Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. *Kidney Int*. 2014 Sep;86(3):638-47. doi: 10.1038/ki.2014.58. Epub 2014 Mar 19.
3. Floege J, Covic AC, Ketteler M, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. *Nephrol Dial Transplant*. 2015 Jun;30(6):1037-46. doi: 10.1093/ndt/gfv006. Epub 2015 Feb 16.
4. Floege J, Covic AC, Ketteler M, et al. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. *Nephrol Dial Transplant*. 2017 Nov 1;32(11):1918-1926. doi: 10.1093/ndt/gfw460.
5. Greenbaum LA, Jeck N, Klaus G, et al. Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease. *Pediatr Nephrol*. 2021 May;36(5):1233-1244. doi: 10.1007/s00467-020-04805-y. Epub 2020 Oct 27.

6. Ketteler M et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. *Ann Intern Med.* 2018;168(6):422-430.
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int.* 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018. PMID: 38490803.
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). *Kidney Int.* 2017;7(suppl 1):1-59. doi:10.1016/j.kisu.2017.04.001
9. Kovesdy CP, Lu JL, Wall BM, et al. Changes with lanthanum carbonate, calcium acetate, and phosphorus restriction in CKD: a randomized controlled trial. *Kidney Int Rep.* 2018;3(4):897-904. doi:10.1016/j.ekir.2018.03.011
10. Li M, Kang Y, Zhang C, Ni X. Comparison of the efficacy of sucroferric oxyhydroxide and lanthanum carbonate in the hyperphosphatemia of maintainable Hemodialysis. *BMC Pharmacol Toxicol.* 2025 Apr 9;26(1):78. doi: 10.1186/s40360-025-00914-2.
11. Locatelli F, Del Vecchio L. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients? *J Nephrol.* 2017;30(6):755-765. doi:10.1007/s40620-017-0421-y.
12. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children with Chronic Kidney Disease. *Am J Kidney Dis.* 2005;464.
13. Sanchez-Alvarez JE, Astudillo Cortés E, Seras Mozas M,. Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease in Asturias. FOSFASTUR study. *Nefrologia (Engl Ed).* 2021 Jan-Feb;41(1):45-52. doi: 10.1016/j.nefro.2021.02.005. Epub 2021 Mar 1.
14. Velphoro (sucroferric oxyhydroxide) [prescribing information]. Waltham, MA: Fresenius Medical Care North America; March 2026.
15. Zhu Y, Rao J, Liao X, Ou J, Li W, Xue C. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials. *Int Urol Nephrol.* 2021 Sep;53(9):1899-1909. doi: 10.1007/s11255-021-02820-y. Epub 2021 Mar 6.

#### Clinical Guideline Revision / History Information

Original Date: 9/21/2023

Reviewed/Revised: 09/18/2024, 10/01/2025, 08/03/2026